INSPECTIONS DONE WITH NO FINDINGS AND MORE APPROVALS COMING!!!!!!!!
Which one will it be?
Generic version of Norco - $700 million according to IMS Health data.
Generic version of OxyContin - IMS reported approximately $2.3 billion in revenue for OxyContin® and its equivalents in 2016.
December 2018 (10 months) to Early 2019 - Elite/SunGen - generic version of an immediate release central nervous system (“CNS”) stimulant - IMS Health data, the branded product and its equivalents had total U.S. sales of more than $400 million for the twelve months ended September 30, 2017.
March 2019 (10 months) - Elite/SunGen - generic version of an extended release CNS stimulant - total U.S. sales of approximately $1.6 billion for the twelve months ended September 30, 2017.
Approved - generic version of Percocet - QuintilesIMS Health data for the twelve months ending May 31, 2018, the retail sales for the brand and generic products were approximately $500 million.
APPROVED! - generic version of a synthetic narcotic analgesic - Based on QuintilesIMS Health data, the annual retail sales for the brand and generic products were approximately $30 million.
Billions $$ in market potential coming to ELITE PHARMA IN less than a year!!!!!!!!
JUST 1% for the 2 approved puts ELITE at $5.3 MILLION, 5% = $26.5 MILLION. Revenue IS COMING!!!!!!!!
$500 million + $700 Million + $30 million + $2.3 BILLION + $400 million + $1.6 BILLION = $5.44 BILLION market opening up to Elite (ELTP).
